{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alemtuzumab+%28Campath+%29&page=2", "query": { "intervention": "Alemtuzumab (Campath )", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 279, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alemtuzumab+%28Campath+%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alemtuzumab+%28Campath+%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T07:01:30.566Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01679041", "title": "High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seah Lim M.D.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 1, "start_date": "2012-11", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 3, "location_summary": "Amarillo, Texas", "locations": [ { "city": "Amarillo", "state": "Texas" }, { "city": "Amarillo", "state": "Texas" }, { "city": "Amarillo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01679041" }, { "nct_id": "NCT00448357", "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "rabbit anti-thymocyte globulin (ATG)", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 54, "start_date": "2005-10", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448357" }, { "nct_id": "NCT03591380", "title": "CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 3, "start_date": "2019-05-14", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03591380" }, { "nct_id": "NCT00040469", "title": "Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Anemia", "Hemoglobinopathy", "Thalassemia" ], "interventions": [ { "name": "Campath -1H", "type": "DRUG" }, { "name": "Dilantin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "64 Years", "sex": "ALL", "summary": "1 Day to 64 Years" }, "enrollment_count": 15, "start_date": "2000-08", "completion_date": "2003-11-21", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040469" }, { "nct_id": "NCT01269385", "title": "Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Stage 0 Chronic Lymphocytic Leukemia", "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "PGG beta-glucan", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "DNA analysis", "type": "GENETIC" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "mutation analysis", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "GENETIC" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-01", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01269385" }, { "nct_id": "NCT00105235", "title": "Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Disease", "Liver Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Liver transplant", "type": "PROCEDURE" }, { "name": "Immunosuppression withdrawal", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2005-06", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-12-27", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00105235" }, { "nct_id": "NCT00977691", "title": "Haploidentical PBMC Transplant for Severe Congenital Anemias", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Anemia" ], "interventions": [ { "name": "PBSC Transplant", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Low Dose Irradiation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "2 Years to 80 Years" }, "enrollment_count": 23, "start_date": "2009-12-14", "completion_date": "2026-09-10", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00977691" }, { "nct_id": "NCT00943592", "title": "Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Hematologic Malignancies", "Leukemia", "Preleukemia" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Campath", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 82, "start_date": "2006-03", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-02-27", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943592" }, { "nct_id": "NCT00046683", "title": "Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Cell Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2001-07", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-07-28", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 20, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Fort Myers, Florida + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Hines", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046683" }, { "nct_id": "NCT03421756", "title": "Stem Cell Transplant in Patients With Severe Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Kathleen Dorritie", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-03-29", "completion_date": "2022-05-15", "has_results": false, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-10-07T07:01:30.566Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03421756" } ] }